내시경 클립 시장 : 제품 유형별, 재질별, 용도별, 최종사용자별, 유통 채널별 - 세계 예측(2026-2032년)

The Endoscopic Clips Market was valued at USD 438.90 million in 2025 and is projected to grow to USD 470.99 million in 2026, with a CAGR of 6.83%, reaching USD 697.19 million by 2032.

A concise orientation to contemporary endoscopic clip applications, device evolution, and the strategic imperatives driving clinical adoption and procurement decisions

Endoscopic clips have become an indispensable component of contemporary endoscopic practice, evolving from rudimentary hemostatic tools into versatile devices used across a broad range of therapeutic procedures. As minimally invasive techniques continue to expand, clinicians increasingly rely on clips to manage gastrointestinal hemorrhage, close iatrogenic and traumatic perforations, assist in submucosal dissections, and facilitate tissue approximation tasks such as suturing assistance and fistula closure. The technology underpinning clips now spans distinct delivery mechanisms, refined materials, and design innovations that together shape clinical workflows and procurement decisions.

Over the past decade, manufacturers and clinical experts have refined both device mechanics and application protocols, driving greater confidence among endoscopists to perform complex interventions endoscopically rather than surgically. This shift accompanies improvements in visualization, endoscope capabilities, and adjunctive devices used during procedures. In parallel, purchasers and clinical leaders are placing greater emphasis on device compatibility with existing endoscopy platforms, sterility pathways, and supply chain resilience. Consequently, a clear understanding of product types, applications, channels of distribution, and the material science that informs clip performance is essential for stakeholders seeking to align innovation with clinical needs and institutional budgets.

This report's executive perspective synthesizes the most salient clinical, commercial, and regulatory trends shaping the endoscopic clip landscape. It aims to equip executives, clinical champions, and investors with a concise yet comprehensive framework for evaluating product portfolios, identifying growth levers, and preparing organizational responses to evolving reimbursement and trade environments.

How shifts in procedural practice, device materials, and distribution models are collectively redefining clinical workflows and commercial adoption in endoscopic clipping

The endoscopic clip landscape is undergoing a confluence of transformative shifts driven by clinical practice changes, material science developments, and procedural innovation. Clinicians are adopting more advanced endoscopic therapies, leading to the wider use of both Over-The-Scope and Through-The-Scope systems for increasingly complex interventions. Over-The-Scope designs that employ cap mounted clips or dual-thread mechanisms have expanded therapeutic reach, while Through-The-Scope variants, available as coated and uncoated clips, emphasize ease of deployment and compatibility with a broader range of endoscope channels.

Material innovations are reshaping device profiles and clinical expectations. Metal alloys such as stainless steel and titanium remain foundational for reliability and radial strength, whereas bioresorbable polymers like polyglycolic acid and polylactic acid are gaining traction where temporary tissue approximation is desirable. These material shifts influence clinician preference, regulatory pathways, and inventory management, since resorbable options can mitigate long-term foreign-body concerns but introduce new considerations for storage and handling.

Procedural workflows are also shifting as applications diversify. The treatment of gastrointestinal hemorrhage increasingly differentiates between upper and lower GI sources, and techniques for submucosal dissection now span colorectal, esophageal, and gastric interventions. End users from ambulatory surgery centers to specialty clinics are adapting logistics and training to accommodate these therapies. Concurrently, distribution and procurement models are evolving; some healthcare systems favor direct purchasing to secure product continuity and pricing predictability, while others rely on distributors, including online channels and wholesalers, to provide flexibility and breadth of supply. These interlocking trends create a dynamic environment where clinical efficacy, device economics, and supply reliability determine adoption trajectories.

Analysis of how 2025 United States tariff actions altered supply chains, procurement behavior, and manufacturer strategies to preserve clinical access and innovation

The introduction of United States tariff actions in 2025 introduced a new variable into the global supply chain calculus for endoscopic clip manufacturers, distributors, and healthcare procurement teams. Tariffs on specific components and finished devices raised the cost of imported raw materials and assemblies for many suppliers that source stainless steel, titanium, polymer precursors, and manufactured clips from international partners. In response, manufacturers weighed alternative sourcing strategies, adjusted contract terms with suppliers, and revisited inventory policies to mitigate exposure to cost volatility.

Downstream, procurement professionals at hospitals, ambulatory surgery centers, and specialty clinics re-evaluated total cost of ownership for clip families and considered greater emphasis on domestic production, local suppliers, and longer-term supply agreements. Some organizations accelerated qualification of multiple vendors to ensure continuity of supply, while others sought to renegotiate pricing and payment terms. These procurement adjustments were often accompanied by clinical reassessments to determine where resorbable polymer options or different clip designs could deliver comparable clinical outcomes with reduced exposure to tariff-driven cost pressures.

Concurrently, manufacturers pursued operational changes to absorb or redistribute tariff impacts without compromising access. Strategies included redesigning packaging and assembly workflows to minimize imported content subject to tariffs, increasing local manufacturing footprints where economically feasible, and optimizing logistics to avoid tariff triggers. Partnerships with distributors evolved as both sides worked to balance margin preservation with the imperative to maintain stable supply chains for end users. Ultimately, the tariff environment underscored the importance of supply chain transparency, scenario planning, and agile commercial models to preserve clinical access and sustain investment in product innovation.

Deconstructing the market through interlocking segmentation lenses to reveal where product design, materials, and end-user dynamics drive differentiated clinical adoption

A granular view of segmentation clarifies where innovation and adoption pressures are concentrated and why product strategy must be multidimensional. When the market is viewed by product type, two dominant families emerge: systems designed Over-The-Scope and those deployed Through-The-Scope. Over-The-Scope tools subdivide into cap mounted clip designs that prioritize broad tissue capture and dual-thread clips that enable controlled constriction, each serving different procedural needs and operator preferences. Through-The-Scope designs present both coated and uncoated clip variants; coated clips often focus on reducing tissue trauma and improving visibility, while uncoated clips emphasize cost-effectiveness and broad compatibility with existing endoscope channels.

Application-based segmentation surfaces distinct clinical demands that guide design priorities. Gastrointestinal hemorrhage management differentiates between upper and lower GI sources, which impacts clip strength, opening span, and deployment ergonomics. Perforation closure requires options suitable for both iatrogenic and traumatic etiologies, emphasizing rapid deployability and secure tissue apposition. Submucosal dissection procedures vary by anatomic site-colorectal, esophageal, and gastric-and each location imposes unique access and angulation challenges. Tissue approximation use cases, such as endoscopic suturing assistance and fistula closure, push devices toward multi-stage utility where clips either facilitate or complement suturing strategies.

End-user segmentation further influences adoption pathways. Ambulatory surgery centers, differentiated into gastroenterology-focused centers and multispecialty facilities, seek efficient disposable profiles and predictable inventory models. Hospitals, including general and teaching institutions, demand extensive product portfolios that support both routine procedures and complex interventions used in training environments. Specialty clinics, whether endoscopy centers or outpatient clinics, prioritize devices that maximize throughput while ensuring procedural efficacy. Distribution channel choices-whether direct procurement or reliance on distributors that operate through online platforms and wholesalers-affect lead times, pricing, and the availability of newer materials. Finally, material segmentation highlights trade-offs between metal and polymer constructs: stainless steel and titanium deliver established mechanical performance and radiopacity, while polyglycolic acid and polylactic acid offer resorbability and distinct biological interaction profiles. These intersecting segmentation dimensions inform product roadmaps, clinical education strategies, and supply chain designs for stakeholders seeking to match device attributes to procedural and institutional needs.

Regional regulatory, reimbursement, and clinical adoption contrasts that compel differentiated commercialization strategies across major global geographies

Regional dynamics exhibit distinct regulatory, reimbursement, and clinical practice characteristics that shape device selection and commercialization strategies. In the Americas, clinical adoption is influenced by a diverse mix of private and public healthcare delivery settings, where institutions often balance cost control with demand for minimally invasive therapies. U.S. regulatory pathways and procurement protocols tend to emphasize evidence of clinical benefit and compatibility with existing endoscopy platforms, encouraging manufacturers to prioritize interoperability and procedural training support.

Europe, Middle East & Africa presents a heterogeneous environment with variable reimbursement frameworks and differing levels of clinical infrastructure. Western European markets frequently require robust clinical data and post-market surveillance, while emerging markets in parts of the region prioritize affordability and supply chain accessibility. Regulatory harmonization efforts in parts of Europe coexist with localized commissioning decisions, prompting manufacturers to adopt regionally tailored access strategies that pair clinical education with cost-effective delivery models.

Asia-Pacific encompasses settings with rapid adoption of advanced endoscopic techniques alongside markets that remain capacity-constrained. Clinician preference for novel devices in several Asia-Pacific centers drives interest in both high-performance metal clips and bioresorbable polymer options, but local procurement processes and manufacturing partnerships often determine which products attain scale. Across all regions, cross-border supply chain resilience, clinician training programs, and adaptable commercial strategies remain decisive factors in realizing clinical and commercial success.

Competitive positioning driven by device differentiation, clinician partnership models, and supply chain resilience that together determine long-term market leadership

Competitive dynamics in the endoscopic clip space reflect a balance between engineered performance, clinical support, and commercial reach. Leading device developers differentiate through product portfolios that combine distinct deployment mechanisms, material innovations, and clinician-focused training. Some firms concentrate on optimizing Over-The-Scope systems for high-complexity interventions, investing in cap mounted and dual-thread designs that expand therapeutic capability. Others emphasize Through-The-Scope solutions that offer straightforward integration into established endoscopy workflows, featuring coated variants that address tissue interaction and uncoated options that reduce unit costs.

Strategic activity also centers on partnerships and channel expansion. Manufacturers frequently collaborate with academic centers to generate clinical evidence and refine procedural techniques, while distributor alliances expand geographic access and supply continuity. Investment in clinician training and procedural education is a differentiator; companies that provide hands-on workshops, simulation tools, and procedural proctorship tend to accelerate clinical uptake. On the operational side, supply chain agility and vertical integration into component sourcing or local manufacturing can protect margins and reduce exposure to trade disruptions. Collectively, these competitive behaviors create an environment where firms that combine technical differentiation, clinician engagement, and resilient commercial models are best positioned to capture clinical preference and long-term loyalty.

A pragmatic action plan for device developers and healthcare leaders to align product innovation, clinician education, and supply chain safeguards for sustained adoption

Industry leaders should pursue a coordinated playbook that bridges clinical utility and commercial resilience. First, aligning product development with clinician-identified procedural pain points yields designs that are more likely to achieve clinical endorsement; concentrating R&D on features such as controlled deployment mechanics for perforation closure, variable span options for hemorrhage control across upper and lower GI, and materials suited for temporary tissue support will enhance clinical relevance. Second, integrating robust clinician education-ranging from hands-on training to remote proctoring and procedural content-will accelerate meaningful adoption by reducing the learning curve for advanced interventions.

Operationally, diversifying component sourcing and expanding local manufacturing partnerships can mitigate exposure to trade policy shifts and tariffs. Contractual strategies that include multi-supplier qualification and longer-term agreements with distributors help stabilize supply and pricing. Commercially, creating differentiated value propositions for hospitals, ambulatory surgery centers, and specialty clinics enables more precise targeting; hospitals may prioritize extensive portfolios and training support, whereas ambulatory centers might emphasize device efficiency and predictable reordering. Finally, investing in post-market evidence generation and real-world data collection strengthens reimbursement dialogues and reinforces product credibility with clinical decision makers. Together, these actions form a pragmatic roadmap for sustaining growth while maintaining clinical leadership.

Transparent and defensible mixed-methods research approach combining clinician interviews, regulatory review, and product evidence synthesis for actionable insights

The research underlying these insights combined structured primary interviews, targeted secondary research, and qualitative synthesis to ensure balanced perspective and practical relevance. Primary work included structured conversations with practicing endoscopists, procurement leaders across hospitals and ambulatory settings, and senior commercial executives from device manufacturers and distributors. These discussions focused on procedural preferences, device selection criteria, inventory management, and responses to supply disruptions.

Secondary inputs comprised peer-reviewed clinical literature, regulatory guidance documents, manufacturer product specifications, and publicly disclosed corporate communications. Emphasis was placed on cross-validating clinical claims with independent procedural outcomes and on mapping product features to real-world clinical workflows. The analysis also incorporated scenario-based assessments of supply chain and trade policy impacts to illuminate operational priorities and strategic options. Finally, the methodology applied iterative synthesis to reconcile practitioner experience with documented evidence and commercial disclosures, producing insights designed to be actionable for clinical and executive audiences.

Synthesis of clinical, commercial, and regulatory imperatives that define the path forward for durable adoption and procedural advancement

Endoscopic clips occupy a strategic role at the intersection of clinical innovation and procedural economics. Advancements in deployment mechanisms, material science, and procedural techniques have broadened therapeutic possibilities while also raising new expectations for clinician training, supply chain robustness, and evidence generation. Stakeholders that successfully align device performance with practical clinical needs and resilient commercial models will be better placed to support the ongoing shift toward minimally invasive care.

In the context of evolving trade dynamics and regional variability in regulatory and reimbursement frameworks, adaptability is paramount. Manufacturers should focus on modular product strategies, strengthen clinician partnerships, and build flexible sourcing architectures. Healthcare providers should prioritize device compatibility, training pathways, and procurement practices that preserve access during periods of policy or supply volatility. Together, coordinated action across the ecosystem can maintain clinical momentum and ensure that device innovation translates into improved patient outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Endoscopic Clips Market, by Product Type

• 8.1. Over-The-Scope
  • 8.1.1. Cap Mounted Clip
  • 8.1.2. Dual-Thread Clip
• 8.2. Through-The-Scope
  • 8.2.1. Coated Clip
  • 8.2.2. Uncoated Clip

9. Endoscopic Clips Market, by Material

• 9.1. Metal
  • 9.1.1. Stainless Steel
  • 9.1.2. Titanium
• 9.2. Polymer
  • 9.2.1. Polyglycolic Acid
  • 9.2.2. Polylactic Acid

10. Endoscopic Clips Market, by Application

• 10.1. Gastrointestinal Hemorrhage
  • 10.1.1. Lower Gastrointestinal
  • 10.1.2. Upper Gastrointestinal
• 10.2. Perforation Closure
  • 10.2.1. Iatrogenic
  • 10.2.2. Traumatic
• 10.3. Submucosal Dissection
  • 10.3.1. Colorectal
  • 10.3.2. Esophageal
  • 10.3.3. Gastric
• 10.4. Tissue Approximation
  • 10.4.1. Endoscopic Suturing Assistance
  • 10.4.2. Fistula Closure

11. Endoscopic Clips Market, by End User

• 11.1. Ambulatory Surgery Centers
  • 11.1.1. Gastroenterology Centers
  • 11.1.2. Multispecialty Centers
• 11.2. Hospitals
  • 11.2.1. General Hospitals
  • 11.2.2. Teaching Hospitals
• 11.3. Specialty Clinics
  • 11.3.1. Endoscopy Centers
  • 11.3.2. Outpatient Clinics

12. Endoscopic Clips Market, by Distribution Channel

• 12.1. Direct
• 12.2. Distributor
  • 12.2.1. Online Distributors
  • 12.2.2. Wholesalers

13. Endoscopic Clips Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Endoscopic Clips Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Endoscopic Clips Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. United States Endoscopic Clips Market

17. China Endoscopic Clips Market

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025
• 18.5. B. Braun Melsungen AG
• 18.6. Boston Scientific Corporation
• 18.7. ConMed Corporation
• 18.8. ConMed Corporation
• 18.9. Cook Medical LLC
• 18.10. Ethicon, Inc.
• 18.11. Fujifilm Holdings Corporation
• 18.12. FUJIFILM Holdings Corporation
• 18.13. HOYA Corporation
• 18.14. Karl Storz SE & Co. KG
• 18.15. Medtronic plc
• 18.16. Olympus Corporation
• 18.17. Olympus Corporation
• 18.18. STERIS plc
• 18.19. Teleflex Incorporated